News

Agilent Technologies (A) reported $1.74 billion in revenue for the quarter ended July 2025, representing a year-over-year increase of 10.1%. EPS of $1.37 for the same period compares to $1.32 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $1.66 billion, representing a surprise of +4.6%. The company delivered an EPS surprise of +0.74%, with the consensus EPS estimate being $1.36.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Revenue- Life Sciences and Diagnostics Markets Segment: $670 million versus the three-analyst average estimate of $631.29 million. The reported number represents a year-over-year change of -14.3%.
• Net Revenue- Applied Markets: $324 million versus $308.76 million estimated by three analysts on average.
• Net Revenue- Agilent Crosslab Group: $744 million versus $720.15 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +81% change.
• Revenue by End Markets- Chemical and advanced materials: $399 million versus the two-analyst average estimate of $376.71 million. The reported number represents a year-over-year change of +12.1%.
• Revenue by End Markets- Environmental and Forensics: $163 million versus the two-analyst average estimate of $170.7 million. The reported number represents a year-over-year change of -3%.
• Revenue by End Markets- Diagnostics and Clinical: $258 million compared to the $249.8 million average estimate based on two analysts. The reported number represents a change of +6.6% year over year.
• Revenue by End Markets- Academia and Government: $132 million versus $137.61 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3.1% change.
• Revenue by End Markets- Pharmaceutical: $629 million versus $581.31 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +16.5% change.
• Revenue by End Markets- Food: $157 million versus $150.33 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9% change.

Shares of Agilent have returned -1.3% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.

See "2nd Wave" AI stocks now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.